Claims for Patent: 11,207,311

Summary for Patent: 11,207,311

Title:	Method of treating prostate cancer
Abstract:	Disclosed are methods of treating prostate cancer by administering niraparib to a human in need thereof.
Inventor(s):	Gottardis Marco, Hawkins Rebecca, Snyder Linda A, Yamada Douglas H
Assignee:	Janssen Pharmaceutica NV
Application Number:	US16131772
Patent Claims:	2. The method of claim 1 , wherein the prostate cancer is castration-resistant prostate cancer.3. The method of claim 1 , wherein the human is carrying at least one DNA repair anomaly selected from the group consisting of FANCA claim 1 , PALB2 claim 1 , CHEK2 claim 1 , BRIP1 claim 1 , HDAC2 claim 1 , and ATM.4. The method of claim 1 , wherein the human is not BRCA deficient.5. The method of claim 1 , wherein the prostate cancer is metastatic castration-resistant prostate cancer.6. The method of claim 1 , wherein niraparib or a salt thereof is administered in an amount of from about 30 mg niraparib/day to about 400 mg niraparib/day.7. The method of claim 1 , wherein niraparib or a salt thereof is administered in an amount of about 300 mg niraparib/day.8. The method of claim 7 , wherein niraparib or a salt thereof is administered orally claim 7 , once daily claim 7 , in 100 mg niraparib oral dosage forms.10. The method of claim 9 , wherein the human is not BRCA deficient.11. The method of claim 9 , wherein the human is carrying at least one DNA repair anomaly selected from the group consisting of FANCA claim 9 , PALB2 claim 9 , CHEK2 claim 9 , BRIP1 claim 9 , HDAC2 claim 9 , and ATM.12. The method of claim 3 , wherein niraparib or a salt thereof is administered in an amount of from about 30 mg niraparib/day to about 400 mg niraparib/day.13. The method of claim 3 , wherein niraparib or a salt thereof is administered in an amount of about 300 mg niraparib/day.14. The method of claim 4 , wherein niraparib or a salt thereof is administered in an amount of from about 30 mg niraparib/day to about 400 mg niraparib/day.15. The method of claim 4 , wherein niraparib or a salt thereof is administered in an amount of about 300 mg niraparib/day.16. The method of claim 1 , wherein the human has had at least one line of taxane-based chemotherapy.17. The method of claim 3 , wherein the human has had at least one line of taxane-based chemotherapy.18. The method of claim 4 , wherein the human has had at least one line of taxane-based chemotherapy.19. The method of claim 9 , wherein the human has had at least one line of taxane-based chemotherapy.20. The method of claim 10 , wherein the human has had at least one line of taxane-based chemotherapy.21. The method of claim 1 , wherein the prostate cancer has been exposed to at least one line of enzalutamide- claim 1 , apalutamide- claim 1 , or abiraterone acetate-based chemotherapy.22. The method of claim 3 , wherein the prostate cancer has been exposed to at least one line of enzalutamide- claim 3 , apalutamide- claim 3 , or abiraterone acetate-based chemotherapy.23. The method of claim 4 , wherein the prostate cancer has been exposed to at least one line of enzalutamide- claim 4 , apalutamide- claim 4 , or abiraterone acetate-based chemotherapy.